Baseline disease characteristics were comparable (Table 1). Subjects had a baseline EGSS of 3 - moderate (90.9%, N=1467) or 4 - severe (9.1%, N=147). Mean (SD) inflammatory and noninflammatory lesion counts were 28.1 (7.12) and 41.1 (16.54).
Efficacy Evaluation
Evaluator’s Global Severity Score (EGSS)
Tazarotene 0.045% lotion was significantly more effective than vehicle in achieving treatment success (Figure 2), defined as at least a 2-grade improvement in EGSS and ‘clear’/’almost clear’. By week 12, 25.5%, and 29.6% (Study 1 and 2) of subjects in the tazarotene 0.045% lotion groups achieved this co-primary efficacy outcome compared with 13.0% and 17.3% with vehicle (both P<0.001). In addition, 28.3% and 34.5% (Study 1 and 2)
Efficacy Evaluation
Evaluator’s Global Severity Score (EGSS)
Tazarotene 0.045% lotion was significantly more effective than vehicle in achieving treatment success (Figure 2), defined as at least a 2-grade improvement in EGSS and ‘clear’/’almost clear’. By week 12, 25.5%, and 29.6% (Study 1 and 2) of subjects in the tazarotene 0.045% lotion groups achieved this co-primary efficacy outcome compared with 13.0% and 17.3% with vehicle (both P<0.001). In addition, 28.3% and 34.5% (Study 1 and 2)
